碧海银沙1112015-04-11 12:21
Cellectis公司(ALCLS)(市场:ALCLS–纳斯达克全球市场:CLLS)一个开创性的基因排序公司在免疫肿瘤学领域采用专有技术开发最好的一流产品,今天宣布Cellectis公司将出席以下即将举行的会议:
波士顿癌症进展
日期:星期二,2015年4月14日时间:1:50 pm ET演示;
地点:约瑟夫-马丁会议...查看全文
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014032 Size: 10 KB 网页链接
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014022 Size: 5 KB 网页链接
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014015 Size: 5 KB 网页链接
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014007 Size: 12 KB 网页链接
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014010 Size: 5 KB 网页链接
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014004 Size: 13 KB 网页链接
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014000 Size: 11 KB 网页链接
$Sunesis制药(SNSS)$ 8-K Current report, items 2.01, 3.03, 5.01, 5.02, 5.03, 8.01, and 9.01 Accession Number: 0001193125-21-054723 Act: 34 Size: 91 KB 网页链接
$Sunesis制药(SNSS)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001564590-21-007784 Act: 34 Size: 8 MB 网页链接
$Sunesis制药(SNSS)$ 8-K Current report, items 5.02 and 5.07 Accession Number: 0001564590-21-007255 Act: 34 Size: 70 KB 网页链接